Optimas Appoints Industry Veteran Phil Battaglia as Chief Financial Officer

WOOD DALE, IL, Apr 18, 2023 – (ACN Newswire) – Optimas Solutions, a global industrial manufacturer/distributor and service provider, announced today the appointment of Phil Battaglia as Chief Financial Officer. Battaglia possesses over 25 years of financial management and reporting expertise, most recently leadership experience at Caterpillar Inc.

Phil Battaglia, CFO of Optimas Solutions. Phil Battaglia comes from Caterpillar to become Optimas Solutions' new CFO.

"We are delighted to have Phil on board in such an important role for us," said Daniel Harms and Mike Tuffy, Optimas' dual CEOs. "As we continue to elevate our business, we needed someone in our CFO position with the financial acumen and customer-oriented thinking that Phil brings to us. We believe Phil will be essential to strengthening Optimas' solid financial foundation and partner with us to ultimately enhance how we serve our customers."

"Optimas is well positioned for a successful future driven by our customers' needs," Battaglia said. "I think I can bring that customer perspective to Optimas given my experience at Caterpillar. While I was there, I worked with suppliers such as Optimas and understand what OEMs want and need. I'm excited about the long-term impact of the Optimas team, its products and processes, not only for us, but more importantly for our customers."

Battaglia comes to Optimas from Caterpillar, where he held various positions including Vice President of Financial Planning & Analysis, CFO of Caterpillar's Product Support & Logistics Division, and Assistant Corporate Treasurer. Prior to Caterpillar, he was an investment banker at Citi where he advised customers in the industrials and mining sectors on M&A and financing transactions. Battaglia holds a BA degree in economics from Northwestern University and is certified by The Institute of Management Accountants.

About Optimas Solutions

Optimas is the leading global industrial distributor and service provider specializing in fastening and supply chain solutions for manufacturers seeking to improve efficiency and profitability. We take care of the details so customers can focus on manufacturing cutting-edge products – giving them an unparalleled competitive edge. Visit optimas.com and follow us on LinkedIn www.linkedin.com/company/optimas-solutions/ and Twitter @Optimas_S.

Contact Information
Meghan Lane
Senior Marketing Manager
meghan.lane@optimas.com
+1 (630) 716-3416

Tom Bryan
Marketing Manager
tom.bryan@optimas.com
44 (0)7725 109294

SOURCE: Optimas Solutions

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Committed to Empowering Customers’ Transition to Net Zero, INNIO Opens Two Training Centers in China

GUANGDONG, CHINA, Apr 18, 2023 – (ACN Newswire) – INNIO Group today announced that it opened two new training centers in China's Guangdong Province. The first center commenced operations on 11 April 2023 in Dongguan City. The second center commenced operations on 14 April 2023 in Zhaoqing. The facilities are INNIO's first Training Centers in China and are operating under the Jenbacher brand name, localizing technical training that helps INNIO's distributors and customers to continue delivering high-quality, reliable service in-country for the entire Jenbacher fleet.

Bright Yin General Manager INNIO's Jenbacher Brand in China

"Providing INNIO's more than 90-plus years of energy solutions expertise is a key part of helping our customers transition to net zero," said Bright Yin, General Manager for INNIO's Jenbacher brand in China. "The Training Centers will complement INNIO's global customer support capabilities – bringing our existing training capabilities closer to China."

INNIO is committed to empowering China to achieve its goals. The country seeks to deploy more organic waste treatment centers such as biomass. INNIO is a leader in China's waste-to-energy industry, with more than 800 Jenbacher units delivered in total across various industries to China. The new Training Centers will meet the growing demand for local training. INNIO's OEM expertise and experienced trainers will provide tailored training programs as well as classroom and hands-on courses, enabling its students to develop skills and knowledge to optimize the value of their Jenbacher plants for customers.

The Training Centers will enhance distributor field service engineers' capabilities, and bridge and link end customer satisfaction. Students at the new local Training Centers will receive on-the-ground mechanical & electrical training courses for all series of Jenbacher products – T3/T4/T6/J624 – in China locally.

While both Training Centers are new, the 400 m2 Jenbacher China Training Center in Dongguan City is located at the site of INNIO's authorized distributor-Camda New Energy Equipment Co., Ltd. The 500+ m2 Jenbacher China Training Center in Zhaoqing is located at the site of INNIO's distributor-Guangzhou Shenfa M&E Industry Development Co., Ltd. These Training Centers underpin INNIO's commitment to employing skilled talent base in the region and supporting regional customer projects.

Globally, each year Jenbacher Training Centers deliver more than 10,000 classroom days. To date, INNIO's global Training Centers documented more than 140,000 field tasks (on-the-job trainings), and more than 155,000 e-trainings have been completed over the years. INNIO's Jenbacher trainers work with students that range from beginners to the highly experienced, using theoretical and practical training, onsite coaching, and digital training.

About INNIO

INNIO is a leading energy solution and service provider that empowers industries and communities to make sustainable energy work today. With our product brands Jenbacher and Waukesha and our digital platform myPlant, we offer innovative solutions for the power generation and compression segments that help industries and communities generate and manage energy sustainably while navigating the fast-changing landscape of traditional and green energy sources. INNIO is individual in scope, but global in scale. With our flexible, scalable, and resilient energy solutions and services, we enable our customers to manage the energy transition along the energy value chain wherever they are in their transition journey.

INNIO is headquartered in Jenbach (Austria), with other primary operations in Waukesha (Wisconsin, U.S.) and Welland (Ontario, Canada). A team of more than 4,000 experts provides life-cycle support to the more than 55,000 delivered engines globally through a service network in more than 100 countries.

INNIO's improved ESG Risk Rating again secures the number one position across more than 500 companies globally in the machinery industry assessed by Sustainalytics.

For more information, visit the INNIO website at http://www.innio.com. Follow INNIO on Twitter and LinkedIn.

Contact Information:
Susanne Reichelt
INNIO Media Relations
susanne.reichelt@innio.com
+43 664 80833 2382

SOURCE: INNIO Group

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

The 21st Conference on International Exchange of Professionals Opens in Shenzhen

SHENZHEN, CHINA, Apr 18, 2023 – (ACN Newswire) – On April 15, the 21st Conference on International Exchange of Professionals (CIEP), co-sponsored by the Ministry of Science and Technology of the PR.China and the Shenzhen Municipal People’s Government and organized by Shenzhen Center for International Exchange of Personnel, opened in Shenzhen. Zhang Guangjun, member of the party group and deputy minister of the Ministry of Science and Technology of the PR.China, delivered a keynote speech and announced the opening of the 21^st CIEP. Liu Hua, director of the World Intellectual Property Organization (WIPO) China Office, read out the congratulatory letter from Deputy Director-General Wang Binying. Okimura Kazuki, honorary chairman of the Japan Science and Technology Agency (JST), Meng Fanli, deputy secretary of the Guangdong Provincial Committee of the CPC and secretary of the Shenzhen Municipal Committee of the CPC, and Wang Xi, member of the Guangdong Provincial Committee of the CPC and vice governor, delivered speeches. Qin Weizhong, deputy secretary and mayor of the Shenzhen Municipal Committee of the CPC, specially invited guests Sir Sohail Shaikh, trade envoy to the British Department for International Trade, Alex Goldman Shayman, Consul General of the Consulate General of Israel in Guangzhou, Prof. Horst Vogel, chief scientist of the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences, Bu Yulong, chairman of Zhongzhi Group, and Wang Huiyao, founder and chairman of the Center for China and Globalization (CCG) attended the opening ceremony.

Zhang Guangjun pointed out that China has always placed scientific and technological innovation at the core of the country’s overall development. Through scientific and technological innovation, China provides more sources for the high-quality development of the country. The overall efficiency of the national innovation system has been significantly improved. In 2022, China ranked 11th in the Global Innovation Index, entering the ranks of innovative countries. At the same time, China actively participates in cutting-edge international innovation and continues to make important contributions to addressing global issues. Looking forward, China will continue to expand extensive and in-depth open cooperation and exchange with countries around the world. China will plan scientific and technological innovation with a global perspective, actively integrate into the global innovation network, promote scientific and technological exchanges and cooperation on a larger scale, wider areas, deeper levels and higher standards, build an open innovation ecosystem with global competitiveness with an inclusive attitude and pragmatic measures, accelerate the construction of an important talent center and innovation highland in the world, and work together to contribute more wisdom and strength to promote human progress and build a beautiful home.

On behalf of the Shenzhen Municipal Committee of the CPC and Municipal Government, Meng Fanli welcomed the attending leaders and guests, and thanked the Ministry of Science and Technology of the PR.China, all sectors of society, various talents and talent institutions and organizations for their care and support for Shenzhen’s development. He said that Shenzhen’s development benefits from innovation and relies on talents. At present, Shenzhen is deeply learning and implementing the important speeches and instructions of General Secretary, the CPC Central Committee Xi Jinping during his inspection in Guangdong. Shenzhen is determined to take the road of Chinese-style modernization and accelerate the construction of an economic center city and modern international metropolis with more global influence. We sincerely look forward to various talents from home and abroad to continue to focus on and support Shenzhen. We warmly welcome you to come to Shenzhen and integrate into Shenzhen. We will continue to deepen reform and opening up, implement more positive, open and effective talent policies, actively improve the strategic layout, do our best to provide services and support, create more first-class platforms and better ecology, and work with the majority of talents to share development opportunities and win a better future.

Wang Xi said that Guangdong is grasping the major opportunity to build a high-level talent highland in the Guangdong-Hong Kong-Macao Greater Bay Area. It is deeply implementing the “five major projects” of strategic talent forging, talent training foundation, talent introduction and quality improvement, talent system reform, and talent ecosystem optimization, and striving to create a new situation in talent work in the new era. In 2022, Guangdong has 1.3 million R&D personnel, established 1,249 postdoctoral research platforms, and over 12,000 postdoctoral fellows. The total number of professionals, technicians and skilled talents reached 8.91 million and 18.5 million respectively, marking new progress in building a talent-strong province. This conference has built a high-level docking service platform for high-level talents and experts at home and abroad, which will surely promote China’s scientific and technological innovation and international talent exchange and cooperation at a higher level and wider scope. We sincerely welcome outstanding talents from all over the world to display their talents and achieve their dreams in this land of innovation and entrepreneurship in Guangdong.

In her congratulatory letter, Wang Binying congratulated the opening of the 21st Conference on International Exchange of Professionals, saying that WIPO believes that China’s innovation and development has a bright future. WIPO is willing to further strengthen cooperation with stakeholders in China to jointly build a more open, balanced, inclusive, active and forward-looking global intellectual property ecosystem, help Chinese cities achieve technological progress and innovation development, and enable people around the world to enjoy the fruits of intellectual property.

Okimura Kazuki said that the JST has always been committed to promoting Sino-Japanese scientific and technological research and exchanges. JST is conducting the “Sakura Science and Technology Program”, a short-term exchange program for Chinese and Asian youth to visit Japan, aiming to stimulate young researchers’ passion for scientific and technological exploration and promote scientific and technological exchanges between Asian countries and Japan. We look forward to strengthening exchanges and understanding between China and Japan, enhancing friendship and achieving sustained and practical cooperation.

The opening ceremony of the conference coincided with the award ceremony of the Shenzhen Innovation and Entrepreneurship International Competition and the Shenzhen Forum: Global Sci-Tech Innovation Cities.

Themed “Promoting scientific and technological innovation, seeking common development and benefiting global talents”, this conference lasts for two days, focusing on the top priority task of high-quality development. Adopting the “dual-engine” (offline and online) model, about 60 forums and activities will be held. 325 employing units have provided more than 7,600 mid- and high-end job vacancies. Nearly 10,000 government representatives, experts, scholars and high-end talents from 28 countries and regions have attended the conference on site.

Shenzhen Center for International Exchange of Personnel

Wang Chan

86 0755-81707961

86 0755-81773121

wangchan@ciep.gov.cn

http://ciep.gov.cn/

SOURCE: Shenzhen Center for International Exchange of Personnel

Indonesia Invites Investment and Collaboration – Hannover Messe 2023

Hamburg, Germany, Apr 18, 2023 – (ACN Newswire) – Indonesia is keen to exhibit its openness to investment and collaboration with all countries to achieve common prosperity, and this month, Indonesia has been named the official partner country for the Hannover Messe 2023 in Germany. "Indonesia is open to cooperation and investment, and let us collaborate to achieve common prosperity," President Joko Widodo said during the Hannover Congress Centrum, Germany, on Sunday local time.

Indonesia is the official partner country for the Hannover Messe 2023, one of the world's largest trade and industrial fairs. The country is also open to investment and cooperation in developing the downstream process and green economy.

With its abundant natural resources, demographic bonus, huge markets, and maintained economy, Indonesia has the capital to be a major player in global industries. "The Making Indonesia 4.0 theme is highly relevant for Indonesia, which is now striving to transform its economy through innovation and technology," President said.

Indonesia aims to secure investment worth Rp30 trillion through its participation as the Official Partner Country at Hannover Messe 2023

According to the Coordinating Minister for Economic Affairs, Airlangga Hartarto, Indonesia expects a number of investment sectors, including the manufacturing sector, especially renewable energy, as well as in industrial areas or special economic zones, and technological innovations, such as neonatal respiratory system medical devices, automotive components, and fertilizer maintenance instruments.

To date, a total of 19 new cooperation agreements have been signed between Indonesia and other countries during the Hannover Messe 2023 event. The 19 cooperation agreements comprise three government-to-business (G2B) agreements and 13 business-to-business (B2B) agreements including cooperation in semiconductors, solar power, medical devices, waste management, chemical industry, development of CNC milling, Internet of Things, digital industry, electric vehicle charging, and battery systems, industrial parks, energy sustainability, and transition, human resources, as well as start-ups and innovation.

The Hannover Messe, based in the German state of Lower Saxony, is the world's leading trade fair for the industry, featuring four thousand companies from various fields that showcase their technologies and solutions for a connected and climate-neutral industry.

President Jokowi officially opened the Indonesian National Pavilion during the Hannover Messe located in Hall 2 of the exhibition venue. The exhibition will run from April 17 to 21, 2023. Indonesia established a 3,000-square-meter pavilion, and 1,500 square meters of it are allocated to hundreds of participating national co-exhibiting institutions and companies.

The Indonesian government involves 157 co-exhibitors to promote their products at the pavilion, including business entities, associations, industrial areas, special economic zones, state-owned enterprises (SOEs), lending agencies, ministries, and public institutions.

A series of seminars, conferences, and business summits will be conducted in the pavilion, involving various business actors, industry players, investors, and economic associations.

The government chose the theme "Infinite Journey" for the exhibition this year to describe Indonesia's journey towards a limitless future with a spirit of optimism and broad future potential.

Partner Country 2023 – Indonesia
As Partner Country to Hannover Messe 2023, Indonesia presents more than 150 exhibiting organizations that range from large industrial companies, small and medium-sized enterprises and startups to industrial estates, industrial associations and government ministries and institutions. Indonesia invites you to discover its potential – join the Partner Country's infinite journey at Hannover Messe. Visit https://https://indonesiahannovermesse.id.

The Ministry of Industry (Kemenperin)
Public Relations Bureau, Jakarta
E: humaskemenperin@gmail.com

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Asia’s insurance leaders to gather at InsureTech Connect Asia in Singapore to discuss the future of insurance

SINGAPORE, Apr 18, 2023 – (ACN Newswire) – The second annual InsureTech Connect Asia will take place in Singapore from May 30 to June 1, 2023, where insurance industry leaders, professionals, and InsurTech providers from across Asia and beyond will convene to share their successes, strategies, and plans for the future of insurance.

The event will kick off with an opening keynote by Sopnendu Mohanty, Chief Fintech Officer at the Monetary Authority of Singapore (MAS). Mr. Mohanty will share his vision of the future of fintech and its impact on the insurance industry. Following the opening keynote, there will be a keynote panel on "Developing a Future Proofed Workforce." The panel will be moderated by Simon Phipps, and will feature Peta Latimer, CEO of Mercer Singapore, Clemens Philippi, CEO Asia of MSIG, and Rishi Srivastava, CEO – Group Agency Distribution of AIA. The panelists will discuss how to develop a workforce that is equipped to tackle the challenges of a rapidly evolving industry.

They will be joined by over 200 leaders representing insurance companies, investors and InsurTechs across Asia sharing their insights as they take the stage with interactive panel discussions over the three days.

Alongside the conference, over 100 InsurTech solution providers, including Income, Aon, Munich Re, Swiss Re and more will be on-floor to showcase how they are transforming the insurance industry in Asia. Additionally, the exhibition will also witness InsurTech startups across the region compete in the ITC Asia Awards finals and the Pitch Competition hosted by Lloyd's Labs.

"We are thrilled to have such esteemed experts and executives from the insurance world joining us for this event," said Tricia Wong, Director of InsureTech Connect Asia. "Their insights and experiences will provide attendees with a comprehensive understanding of the key issues and opportunities facing the industry, and how to prepare for the future."

InsureTech Connect Asia 2023 will take place at Sands Expo & Convention Centre, Singapore from 30 May to 1 June 2023. For more information on InsureTech Connect Asia, please visit https://bit.ly/itcasia23

InsureTech Connect Asia 2023
Date: 30 May – 1 June 2023
Conference opening hours:
Exhibition opening hours
Sands Expo & Convention Centre, Singapore

About InsureTech Connect

InsureTech Connect (ITC) is the world's largest insurtech event, offering unparalleled access to the largest and most comprehensive gathering of tech entrepreneurs, investors, and insurance industry executives from across the globe. ITC has been attended by over 25,000 people from 65+ countries. Founded in 2016, ITC has established itself as the biggest insurtech event in its US location in Vegas and has launched a new venture in APAC with ITC Asia in Singapore. ITC Asia will be held 30 May – 1 June 2023 at Sands Expo & Convention Centre, Marina Bay Sands. ITC is also the leading source of insurtech webinars, knowledge and meetings.

For more information, please visit https://bit.ly/itcasia23

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Coinweb Completes Integration of 4 New Blockchains Delivering Along its Roadmap for Cross-Chain Interoperability

HONG KONG, Apr 18, 2023 – (ACN Newswire) – Coinweb, a layer-2 protocol unifying blockchain's interoperability, announced the success of integrating four more chains into its expandable blockchain infrastructure. Prior to BNB, Polygon, MultiversX (formerly known as Elrond) and Kujira; Bitcoin, Bitcoin Cash, Litecoin and Ethereum were already part of Coinweb's underlying networks. To date, Coinweb has executed over 4 million transactions since December 2020, and is responsible for an average of 0.3% of all daily transactions being broadcast to the BNB chain in March 2023.

With these current eight blockchains integrated, Coinweb continues to prove its bold statement of enabling dApps built on top of Coinweb to take advantage of multiple chains' desired features and the flexibility to migrate seamlessly from one chain to another. Blockchain-agnostic tokens that are created on LinkMint — Coinweb's cross-chain tokenization platform, will now have the option to choose to be embedded in any of these underlying chains, moving between them without the need to hold gas balances of each native layer-1 token. This removes key bottlenecks in delivering interoperability and breaking blockchains out of their individual silos.

"Further proving that projects on Coinweb can run Smart Contract using Ethereum, execute token transactions with MultiversX, store data ledger on Bitcoin, and so on, we have been identifying the optimal mesh of chains to integrate, enhancing features and functionalities of the platform," stated Coinweb CEO & Co-founder Toby Gilbert. "The ability to provide true interoperability without compromising layer-1 consensus is key to delivering blockchain adoption for many large-scale enterprises and blockchain projects that have legitimate concerns tying themselves into one network."

Dove, Co-founder at Kujira, a blockchain built with the Cosmos SDK commented, "As a decentralized ecosystem for protocols, builders and web3 users seeking sustainable FinTech, we are looking forward to this collaboration with Coinweb." He further stated, "We find our mission of providing easy and cost-effective building tools for everyone resonates with Coinweb's existing platform and product offerings. I believe Kujira will play an important role in enabling Coinweb's access to the Cosmos ecosystem in a secure and interoperable manner."

About Coinweb

The Coinweb Protocol is a platform used to run decentralised applications on top of multiple different blockchains using them as one. This allows developers of applications to combine the best properties and functionalities of each blockchain.

Coinweb Labs is a design and build consultancy service that creates custom-built and turnkey solutions for decentralised applications interacting with Web3. Coinweb Labs is responsible for building third-party projects on top of the Coinweb protocol and incubating new projects.

For more information, visit https://coinweb.io
Twitter: @CoinwebOfficial
Telegram: Coinweb.io

Contact information:
Ain Mohd
+66 6143 28757
ain@coinweb.io

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Moolec Science Secures Up to $50 Million in Committed Equity Financing With Nomura

Luxembourg, Apr 18, 2023 – (ACN Newswire) – Moolec Science SA (NASDAQ:MLEC) ("Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, announced today it has entered into a Share Purchase Agreement ("Agreement") with Nomura Securities International, Inc. ("Nomura").

The Agreement provides for a committed equity financing facility under which the Company has the option, but not the obligation, to sell up to the equivalent of $50 million in aggregate gross purchase price of its ordinary shares to Nomura over a 36-month period, subject to the terms of the Agreement. The Company intends to use the proceeds from any future sales of securities under the financing facility, if it is utilized, for general corporate purposes.

"We are pleased to partner with Nomura and secure this financing facility," said Jose Lopez Lecube, Moolec Science's Chief Financial Officer. "This new understanding provides Moolec with enhanced financial flexibility to continue driving forward our Molecular Farming Platform and portfolio of products," he concluded.

Further details are contained in a Current Report on Form 6-K that was filed with the Securities and Exchange Commission today.

About Moolec Science SA

Moolec is a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The Company's technological approach aims to have the cost structure of plant-based solutions with the organoleptic properties and functionality of animal-based ones. Moolec's technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company's product portfolio and pipeline leverages the agronomic efficiency of broadly used target crops, like safflower, soybean, and pea. Moolec has a growing international patent portfolio (23, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of Ph.Ds and Food Insiders, and operates in the United States, Europe, and South America. For more information, visit www.moolecscience.com.

Forward-Looking Statements

This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec Science S.A. ("Moolec") are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in the Form F-1 Registration Statement filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Contact Information
Catalina Jones
Chief of Staff & Sustainability
comms@moolecscience.com

Martin Taraciuk
Investor Relations
ir@moolecscience.com

Michael Bowen
ICR, LLC
moolecir@icrinc.com

Related Files
Moolec Science Secures up to $50 Million Dollars in Committed Equity Financing with Nomura – 2023.04.17.pdf
https://cdn.newswire.com/files/x/a8/e1/bf62a363bcdd61ad9685397e5d2a.pdf

SOURCE: Moolec Science

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Avance Clinical CEO Joins Global BioPharma Panel for Evolution Europe Summit 2023

ADELAIDE, AUS & SAN DIEGO, Apr 18, 2023 – (ACN Newswire) – Avance Clinical the leading award-winning Australian and North American biotech CRO that offers a GlobalReady program to early phase biotech companies to speed up the path to regulatory approval, has been invited to join the Evolution Europe Summit 2023 (Montreux, Switzerland 20 April – 21 April 2023). The panel discussion is focused on the evolution of clinical trials including technology, DCTs, reducing time and cost, drug development planning for approvals, and scaling globally in later phases.

Avance Clinical CEO, Yvonne Lungershausen has been invited to share the Australian and US CRO experience and future projections with a focus on patient centricity and Decentralized Clinical Trials (DCTs) at the Evolution Europe Summit 2023.

Avance Clinical was recently identified by GlobalData as a global leader in DCT technology.

The Evolution Summit is an invitation-only, premium forum bringing leading clinical research executives and innovative solution providers. The summit's content is aligned with key clinical R&D challenges and interests, relevant market developments, and practical and progressive ideas and strategies adopted by successful pioneers. See full details here. https://www.april23.evolution-summit.com/

Avance Clinical has recently been ranked as the world leader in DCT technology adoption by GlobalData and Clinical Trial Arena in the CRO sector. The report found 46% of Avance Clinical's trials incorporated some elements of DCT technologies in 2022 including telemedicine, remote monitoring, and digital data collection.

The DCT report also noted that Avance Clinical's staff training in the latest technologies was a key factor in the ranking. See the full report here. https://www.clinicaltrialsarena.com/features/year-in-review-dct-2022/

Avance Clinical's unique clinical offering GlobalReady enables biotechs that have completed early to mid-phases in Australia to rapidly and seamlessly transition to the US in preparation for FDA approvals, all with the one CRO and dedicated teams across both regions, which reduces time and cost and delivers quality data.

There are currently more than 280 Phase III global trials that have conducted their Phase I study in Australia, which demonstrates Australian data acceptability with the FDA and other major regulatory authorities.

More than 40 biotech clients are now taking advantage of Avance Clinical's GlobalReady program.

This seamless GlobalReady journey is designed so biotechs can:

– Take advantage of the Australian early-phase clinical trial landscape (No IND and 43.5% tax rebate)
– Transition or expand into North America for later phases – without changing CROs (retain study knowledge and processes/team)
– Seamlessly operationalize global dose-escalation and dose-expansion trials across the two regions
– Harness significant speed and cost advantages
– Be assured of quality data – transferable and readily acceptable by the FDA and other regulatory authorities

Find out more:
– Learn about the Australian Advantage here. https://www.avancecro.com/the-australian-advantage/
– Learn about the GlobalReady model here. https://www.avancecro.com/avance-clinical-north-america-operations/
– For more information about the benefits of running your next study with Avance Clinical contact us: enquiries@avancecro.com

About Avance Clinical

Avance Clinical is the largest premium full-service Australian and US CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services. www.avancecro.com

Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past three years, has been providing CRO services in the region for more than 24 years.

Pre-clinical through to Phase 1 and 2
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.

Technology
Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM Watson and Medrio are just some of the technology partners.

Media Contact:
Avance Clinical
Kate Thompson
media@avancecro.com

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Tianyun International: Chairman and CEO of the Group named one of Forbes China’s “2023 GBA ESG Entrepreneur 30”

HONG KONG, Apr 18, 2023 – (ACN Newswire) – Tianyun International Holdings Limited ("Tianyun International", together with its subsidiaries, (the "Group") (Stock Code: 6836.HK), a leading seller and manufacturer of processed fruit products in the People's Republic of China ("PRC"), is pleased to announce that Mr. Yang Ziyuan, Chairman and CEO of the Group, has been listed in Forbes China's "2023 GBA ESG Entrepreneur 30". This prestigious award recognises companies that have demonstrated excellent efforts and contributions in promoting ESG and was presented to Chairman Yang at the Forbes GBA ESG Economic Forum. The selection of 30 ESG Pioneers in the Greater Bay Area was based on international ESG standards, with corporate leadership, industry foresight, innovation drive, and personal impact as the core dimensions.

Mr. Yang Ziyuan, Chairman and CEO of the Group, was presented with the award

Mr. Yang Ziyuan was interviewed by Forbes China with the Group's new sports drink products

Mr. Yang Ziyuan, Chairman and CEO of the Group, said, "I am deeply honoured to be selected as one of the "2023 GBA ESG Entrepreneurs". As a socially responsible enterprise, Tianyun International is committed to upholding ESG principles for sustainable development in green products, talents, corporate governance, and green and low-carbon development, and leading the industry in carrying out quality development. Aligning with China's 'dual carbon' target, the Group has established environmental policies and targets and launched enhanced environmental management projects to reduce our carbon footprint. We will also continue to enhance our corporate governance, boost team cohesion, and fulfil our corporate social responsibility to reward the support and trust of our stakeholders."

"In terms of products, we have been continuously recognised as a "National High-Tech Enterprise" and hold multiple patents for inventions, utility models, and designs. We prioritise comprehensive products research and development to continuously innovate and improve our food production technology standards, ensuring that we deliver high-quality and diversified product mix to both domestic and international markets. As consumer health awareness increases and demand for functional sports drinks rises, we have researched and developed the Fruit Granules Vitamin Sports Drink and Fruit Enzyme Sports Drink to offer consumers with quality products for nutritional supplements and health maintenance. We strongly believe that only through continually improving product quality and innovation, can we truly fulfill our corporate social responsibility and ESG development goals."

"We are grateful for the continued support and trust of the community, and as part of our corporate social responsibility, we will remain committed to enhancing our business and sustainability capabilities. Our focus is to achieve our ESG development goals by fully integrating ESG into our operations and business development. We will also continue to collaborate with our employees, customers, and communities to improve ESG performance, and strive to work closely with stakeholders to promote sustainable and quality development. By doing so, we aim to make meaningful contributions to society, consumers, and the environment."

About Tianyun International Holding Limited (Stock Code: 6836.HK)

Tianyun International Holdings Limited (the "Company") and its subsidiaries (collectively referred to as the "Group") primarily focus on two core business areas: (i) research and development, production, and sales of processed fruit packaged in metal containers, plastic cups, glass containers, and aluminum foil bags and beverages; (ii) trading of fresh fruits. Processed fruit products are sold both under its own brands "Bingo Times", "fruit zz" and "Tiantong Times" and on an OEM basis. The beverages are sold under its own brand Shiok Party and Demon Fruit Season.

The Group is fully committed to providing healthy and safe products to its customers. As a food enterprise with one of the most complete quality certifications, we rigorously adhere to the stringent international production standards and are accredited with BRC (A), IFS Food (High), FDA(FSMA), HALAL, SC, KOSHER, BSCI, and ISO22000, etc. in respect of our production facilities, quality control and management. The Group has also passed the internal food-production standards reviews and audits from several UK and US supermarket chains. Concurrently, as a Chinese food production and export enterprise, the Group upholds "Equal production line; Equal standard; Equal quality" to supply products of equivalent quality to domestic and international markets. The Group's own-brand processed fruit products have continually achieved high market recognition since 2016 and have been awarded the honor and qualification of "China Canned Product Quality Certification Label" by national associations.

The Group was awarded China's Most Promising Listed Companies by the internationally-renowned financial magazine Forbes and the "2017 Linyi Mayor Quality Award" by the PRC government in 2017. The Group's new and proprietary researched, developed, and produced pure fruit snack food, which received a national "Certificate of Invention Patent" in 2018. In 2019 and 2022, the Group was awarded the National Hi-tech Enterprise Certificate for two consecutive terms. In 2020, the Group was recognised as one of the Most Valuable Chinese Brands for the fourth consecutive year. For more information, please visit www.tianyuninternational.com

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Endurance RP: Excellent Positive Results from Phase 3 Randomised Clinical Trial of Fortacin(TM)/Senstend(TM) in China

HONG KONG, Apr 17, 2023 – (ACN Newswire) – Endurance RP Limited ("Endurance" or the "Company" and collectively with its subsidiaries, the "Group"; stock code: 0575.HK) is pleased to announce its commercial strategic partner Wanbang Biopharmaceutical Co., Ltd. ("Wanbang Biopharmaceutical") has successfully completed the Phase 3 double-blind placebo-controlled study of Senstend(TM) in China for the treatment of premature ejaculation ("PE").

The study recorded excellent positive results which met all four co-primary endpoints of Intra-vaginal Ejaculation Latency Time ("IELT"), Index of Premature Ejaculation ("IPE") Ejaculatory Control and IPE Sexual Satisfaction domains and IPE Distress. Compared to both baseline and placebo, Senstend(TM) produced clinically and statistically significant increases in IELT, ejaculatory control and satisfaction and reduction in distress. Consistent with our previous studies undertaken in Europe and the United States ("US"), Senstend(TM) was well-tolerated by both Chinese patients and partners and no new side effects were reported.

In this study, there was a study population of 295 male patients aged 20 years or above who were diagnosed with PE, with 197 patients in the Senstend(TM) group and 98 in the placebo group. Patients were treated for three months at multiple sites in China.

Jamie Gibson, CEO of the Group, said, "We are delighted with the highly significant and positive results from the Phase 3 clinical study in China, which reinforces the results from the European and US Phase 3 clinical studies. This represents an important milestone in the regulatory submission process in China. We now look forward to our commercial partner in China submitting the New Drug Application ("NDA") to National Medical Products Administration ("NMPA") by the end of Q3 2023 with approval expected 12 months later."

Jamie Gibson further added, "Senstend(TM) has the potential to help about 9 million patients in China during its first year of launch, growing to over 170 million by the tenth year. Our strong partner Wanbang Biopharmaceutical, who benefits from being part of the Fosun network. This company has the marketing expertise established e-commerce platforms and an unrivalled nationwide logic and distribution through Sinopharm, China's number one pharmaceutical and healthcare distributor, through its network of hospitals, clinics and pharmacies to ensure the commercial success of Senstend(TM) in China."

Commercial Milestone Payments from Wanbang Biopharmaceutical

All costs of the clinical trials, including any other associated regulatory and submission costs for Senstend(TM) are covered by Wanbang Biopharmaceutical. The group will receive US$5 million (or approximately HK$39 million) (before deduction of PRC withholding tax) assuming NMPA approval for importing Senstend(TM) is granted and US$2 million (or approximately HK$15.60 million) (before deduction of PRC withholding tax) upon first commercial sale of Senstend(TM) in China, from Wanbang Biopharmaceutical.

Additionally, as disclosed on 3 December 2018, there are other significant payments payable to the Group from Wanbang Biopharmaceutical. A payment, which could total up to US$25 million (or approximately HK$195 million) will be made upon the achievement of certain annual net sales milestones by Wanbang Biopharmaceutical and the Group will receive 25 percent of net receipts and tiered percentage royalties on net sales, ranging from the low to high teens, except for circumstances in which a generic product has successfully entered and impacted the market in China, where lower payment structures will apply.

European Market Update

The Company reports positive results in certain countries in the European Union, where Fortacin(TM) has returned to the market. Patients have responded positively, with the first batch of units in Germany experiencing strong demand. The manufacturer has released 30,000 units in February 2023, and the next 30,000 units are scheduled for delivery in July 2023.

About Senstend(TM)
Senstend(TM) (the brand name for Fortacin(TM) in China) is a metered dose aerosol from a proprietary formulation of two marketed drugs, lidocaine and prilocaine, developed for treating premature ejaculation. The disorder affects approximately 20% to 30% of men in China, which translates to a significant initial target male population of approximately 55 million men aged between 20-59 years old, based on World Bank 2022 estimates rising to over 170 million men. In December 2018, Plethora signed an exclusive license agreement with Wanbang Biopharmaceutical Co., Ltd, a wholly controlled company of Shanghai Fosun Pharma, to market Senstend(TM) for premature ejaculation in China.

About Endurance RP Limited (Stock code: 0575.HK)

Endurance is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders since its initial public offering in May 1997.
www.endurancerp.com

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com